ORIC News and Press, Oric Pharmaceuticals Inc. From 01/20/26

2026-01-20 13:36:46 ET ... Read the full article on Seeking Alpha For further details see: ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Jan. 14, 2026 /CNW/ --  Equity-Insider.com News Commentary – The precision oncology market is ...

2026-01-13 16:35:57 ET ORIC Pharmaceuticals, Inc. (ORIC) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 12:45 PM EST... Read the full article on Seeking Alpha For further details see: ORIC Pharmaceuticals, Inc. (ORIC) Presents at 44th Annual J.P. Morgan Healt...

2026-01-12 09:27:53 ET More on ORIC Pharmaceuticals ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript ORIC Pharmaceuticals GAAP EPS of -$0.33 beats by $0.08 Seeking Alpha...

Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data demonstr...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that Jacob M. Chacko, M.D., chief executive offic...

2025-12-07 01:38:52 ET ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer December 6, 2025 8:00 PM EST... Read the full article on Seeking Alpha For further details see: ORIC Pharmaceuticals...

Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity a...

Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development planned in this patient population Company to host a conference call and we...

Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases 36% ORR in median 3L EGFR PACC patients exceeds competitor benchmarks Competitive safety profile, with no significant off-targe...